Lu X - Search Results

1

Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?

Lu X, He M, Yu L, Gou Z. Lu X, et al. Cancer. 2023 May 15;129(10):1492-1501. doi: 10.1002/cncr.34708. Epub 2023 Feb 19. Cancer. 2023. PMID: 36807239 Free article.

2

The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.

Cai S, Zuo W, Lu X, Gou Z, Zhou Y, Liu P, Pan Y, Chen S. Cai S, et al. Among authors: lu x. Front Oncol. 2020 Sep 23;10:1729. doi: 10.3389/fonc.2020.01729. eCollection 2020. Front Oncol. 2020. PMID: 33072554 Free PMC article.

3

Effects of postmastectomy radiotherapy on survival in different age groups for patients with T3N0M0 breast cancer.

He MT, Lu XX, Gou ZC. He MT, et al. Breast. 2021 Dec;60:247-254. doi: 10.1016/j.breast.2021.11.006. Epub 2021 Nov 16. Breast. 2021. PMID: 34808436 Free PMC article.

4

Trends in axillary surgery and clinical outcomes among breast cancer patients with sentinel node metastasis.

Gou Z, Lu X, He M, Yu L. Gou Z, et al. Among authors: lu x. Breast. 2022 Jun;63:9-15. doi: 10.1016/j.breast.2022.02.014. Epub 2022 Mar 1. Breast. 2022. PMID: 35245747 Free PMC article.

5

A novel risk model based on immune response predicts clinical outcomes and characterizes immunophenotypes in triple-negative breast cancer.

Lu X, Gou Z, Yu L, Bu H. Lu X, et al. Am J Cancer Res. 2022 Aug 15;12(8):3913-3931. eCollection 2022. Am J Cancer Res. 2022. PMID: 36119814 Free PMC article.

6

Prognostic value and tumour microenvironment characteristics of the Glasgow Microenvironment Score in primary triple-negative breast cancer.

Lu X, Wang Y, He M, Gou Z. Lu X, et al. J Clin Pathol. 2024 Jan 18;77(2):128-134. doi: 10.1136/jcp-2022-208601. J Clin Pathol. 2024. PMID: 36600565

7

Combining the tumor-stroma ratio with tumor-infiltrating lymphocytes improves the prediction of pathological complete response in breast cancer patients.

Li F, Chen H, Lu X, Wei Y, Zhao Y, Fu J, Xiao X, Bu H. Li F, et al. Among authors: lu x. Breast Cancer Res Treat. 2023 Nov;202(1):173-183. doi: 10.1007/s10549-023-07026-7. Epub 2023 Aug 1. Breast Cancer Res Treat. 2023. PMID: 37528265

8

Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer.

Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, Bu H. Lu X, et al. J Immunother Cancer. 2024 Aug 12;12(8):e009587. doi: 10.1136/jitc-2024-009587. J Immunother Cancer. 2024. PMID: 39134345 Free PMC article.

9

PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.

Yu TJ, Liu YY, Li XG, Lian B, Lu XX, Jin X, Shao ZM, Hu X, Di GH, Jiang YZ. Yu TJ, et al. Among authors: lu xx. Cancer Res. 2021 Nov 1;81(21):5491-5505. doi: 10.1158/0008-5472.CAN-21-0747. Epub 2021 Aug 18. Cancer Res. 2021. PMID: 34408002

10

Prognostic significance of ER-to-PR difference in ER+/HER2- early breast cancer.

Wu X, Zhang W, Lu X, Zhong X, Bu H. Wu X, et al. Among authors: lu x. Sci Rep. 2024 Oct 18;14(1):24431. doi: 10.1038/s41598-024-74608-w. Sci Rep. 2024. PMID: 39424816 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28,607 results

Search Page

Filters